]>
IRCT20240410061465N2 IRCT 2024-04-26 Oroumia University of Medical Sciences Probiotic supplement for Alzheimer's patients LAB Investigating the effect of native engineered probiotic supplement on cognitive function and quality of life of Alzheimer's patients 2024-05-21 anticipated 60 Complete https://irct.ir/trial/76365 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 1 Alzheimer's disease. Intervention 1: Intervention group: Patients with mild to moderate Alzheimer's are over 60 years old, diagnosed by a neurologist, with a small mental state examination score between 10 and 24, the dosage is one pill a day, the duration of use is 12 weeks, the pill is in collaboration with zist Company Fermentation is provided. Intervention 2: Control group: Patients with mild to moderate Alzheimer's are over 60 years old and are diagnosed by a neurologist with a score of the Small Mental Status Examination between 10 and 24. The dosage is one placebo per day, the duration of use is 12 weeks, and the pills are in cooperation with Zist Company fermentation is provided. Yes - There is a plan to make this available What will be shared: A part of the results related to the main result can be shared. When: 6 months after publishing and printing the results To whom: It will be available only to researchers working in academic and scientific institutions Conditions: It can be used if permission is obtained from the person in charge of the design and giving a reference Where to obtain: Project manager at Urmia University of Medical Sciences How to obtain: The application to the research and technology vice-chancellor of the university and after review and approval to the project manager requires 2 working weeks. Comments: Does not have
public Hadi Maleki-Kakelar
3rd Floor, Hakim Jarjani Building, Shafa Street, Ershad Blvd, Cellular and Molecular Research Institute
Urmia Iran (Islamic Republic of) 5719161583 +98 44 3348 6165 Maleki.hadi@umsu.ac.ir Oroumia University of Medical Sciences scientific Hadi Maleki-Kakelar
3rd Floor, Hakim Jarjani Building, Shafa Street, Ershad Blvd, Cellular and Molecular Research Institute
Urmia Iran (Islamic Republic of) 5719161583 +98 44 3348 6165 Maleki.hadi@umsu.ac.ir Oroumia University of Medical Sciences Iran (Islamic Republic of) People with mild to moderate Alzheimer's 60 years no limit Both Patient non-cooperation during treatment Possible death of the patient during the study according to the nature of the disease G30 Alzheimer's disease Treatment - Drugs Placebo Intervention group: Patients with mild to moderate Alzheimer's are over 60 years old, diagnosed by a neurologist, with a small mental state examination score between 10 and 24, the dosage is one pill a day, the duration of use is 12 weeks, the pill is in collaboration with zist Company Fermentation is provided. Control group: Patients with mild to moderate Alzheimer's are over 60 years old and are diagnosed by a neurologist with a score of the Small Mental Status Examination between 10 and 24. The dosage is one placebo per day, the duration of use is 12 weeks, and the pills are in cooperation with Zist Company fermentation is provided. Quality of Life. Timepoint: before the start of the study and after 6 weeks and the end of the study. Method of measurement: questionnaire. Cognitive performance of people. Timepoint: Start and end of study. Method of measurement: questionnaire. Oroumia University of Medical Sciences Approved 2024-03-13 Research Ethics Committees of Urmia University of Medical Sciences No 1, Secend alley, Rodaki Avenue, Urmia, Iran. Urmia West Azarbaijan Iran (Islamic Republic of)